We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App





Human Trial of Pill That Could Reduce COVID-19 Related Lung Damage Begins At First US Clinical Trial Site

By HospiMedica International staff writers
Posted on 11 Aug 2020
Print article
Illustration
Illustration
Ifenprodil, a drug in pill form repurposed by Algernon Pharmaceuticals (Vancouver, BC, Canada) to treat COVID-19 damage in the lungs, is being tested as a possible treatment on coronavirus patients for the first time in the US.

The Westchester General Hospital in Miami, Florida, is the first American research center to test the Ifenprodil pill that was developed in the 1970s to treat blood circulation disorders and could help reduce some COVID-19 side-effects in the lungs. Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB) and prevents glutamate signaling. The NMDA receptor is found on several tissues, including lung cells, T-cells, and neutrophils.

Algernon began exploring Ifenprodil (NP-120) as a possible treatment for COVID-19 when it discovered an independent research study that showed the drug was active in an animal model for H5N1, the world’s most lethal avian flu, with an approximately 60% mortality rate in humans. In the study, Ifenprodil reduced mortality by 40% and reduced acute lung injury and inflammation in the lung tissue. Following its own animal data showing Ifenprodil’s reduction of lung fibrosis in two separate studies, the company is investigating Ifenprodil to determine if it can reduce the severity and duration of a COVID infection. Algernon believes that Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively. The latter can result in the highly problematic cytokine storm that contributes to the loss of lung function and ultimately death as has been reported in COVID-19 infected patients.

Algernon has completed its clinical trial agreement with Westchester Research Center at Westchester General Hospital in Miami, Florida, for its multinational Phase 2b/3 human study of Ifenprodil for COVID-19 and is in final contractual negotiations with four additional US clinical sites. The company has already received ethics approval from a central institutional review board for all of the US study sites. The company is also in the final stages of completing contractual negotiations and receiving ethics approval in Australia, Romania and the Philippines.

“Of the five US research institutions we have been working with, two are located in Florida where they have recently had a significant number of confirmed COVID-19 cases,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “We look forward to working with Dr. Gonzalez and appreciate her work in helping to get the trial started at Westchester General as soon as possible.”

Related Links:

Algernon Pharmaceuticals

New
Gold Member
X-Ray QA Meter
T3 AD Pro
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
New
Transcatheter Heart Valve
SAPIEN 3 Ultra
New
LED Examination Lamp
Clarity 50 LED

Print article

Channels

Critical Care

view channel
Image: This handheld scanner is moved over breast tissue to monitor how well breast cancer tumors respond to chemotherapy or radiation treatment (Photo courtesy of Boston University)

Novel Medical Device Inventions Use Light to Monitor Blood Pressure and Track Cancer Treatment Progress

Traditional blood pressure devices often leave room for human error. To address this, scientists at Boston University (Boston, MA, USA) have developed a new blood pressure monitoring device based on speckle... Read more

Surgical Techniques

view channel
Image: The new treatment combination for subdural hematoma reduces the risk of recurrence (Photo courtesy of Neurosurgery 85(6):801-807, December 2019)

Novel Combination of Surgery and Embolization for Subdural Hematoma Reduces Risk of Recurrence

Subdural hematomas, which occur when bleeding happens between the brain and its protective membrane due to trauma, are common in older adults. By 2030, chronic subdural hematomas are expected to become... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.